Table 1.
Transplant characteristics
| Characteristic | Median (range) or Number (%) |
|---|---|
| Age (in years) | 51 (23–68) |
| Male (sex) | 169 (69) |
| ISS (International Staging System) stage (n = 134) | 2 (1–3) |
| 1 | 41 (30.6) |
| 2 | 47 (35.07) |
| 3 | 46 (34.33) |
| Number of chemotherapy regimen before autologous transplantation (n = 244) | 1 (1–5) |
| 1 | 127 (52.05) |
| 2 | 85 (34.84) |
| 3 | 24 (9.84) |
| 4 | 7 (2.86) |
| 5 | 1 (0.4) |
| Drugs used during induction (n = 244) | |
| Novel agents (bortezomib or lenalidomide) | 128 (52.46) |
| Time from diagnosis to transplantation (in months) | 10.5 (3.9–113.4) |
| Response post induction chemotherapy (n = 239) | |
| Complete response (CR) | 46 (19.25) |
| Very good partial response (VGPR) | 88 (36.82) |
| Partial response (PR) | 89 (37.24) |
| Stable disease (SD) | 10 (4.18) |
| Progressive disease (PD) | 6 (2.51) |
| Mononuclear cell dose (× 108/kg) | 4.99 (0.96–19.64) |
| CD34 cell dose (× 106/kg) | 4.57 (1.15–23.7) |
| Platelet rich concentrate transfusions | 10 (0–78) |
| Packed red cell concentrate transfusions | 1 (0–11) |
| Fresh frozen plasma transfusions | 0 (0–20) |
| Primary engraftment failure | 1 (0.44) |
| Death during peri-transplantation period | 7 (2.86) |
| Cause of death | |
| Invasive fungal infection | 4 |
| Intracranial bleed | 2 |
| Sepsis | 1 |
| Post transplantation response at day 100 (n = 216) | |
| Complete response (CR) | 94 (43.52) |
| Very good partial response (VGPR) | 86 (39.81) |
| Partial response (PR) | 24 (11.11) |
| Stable disease (SD) | 3 (1.39) |
| Progressive disease (PD) | 9 (4.17) |
| Maintenance therapy (n = 216) | 152 (70.37) |
| Interferon (± melphalan) | 19 |
| Thalidomide | 66 |
| Lenalidomide | 59 |
| Bortezomib | 6 |
| Cyclophosphamide and dexamethasone | 2 |
| Duration of maintenance (in months) | 14.5 (1–120) |